Article
FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia.
Clinical lymphoma, myeloma & leukemia - 1 Mar 2022
Novatcheva Elli D, Anouty Yasmine, Saunders Ila, Mangan James K, Goodman Aaron M
Abstract excerpt
Acute myeloid leukemia (AML) is the most common acute leukemia of adults, with a five-year survival that remains poor (approximately 25%). Knowledge and understanding of AML genomics have expanded tremendously over the past decade and are now included in AML prognostication and treatment decisions. FMS-like tyrosine kinase 3 (FLT3) is a Class III receptor tyrosine kinase (RTK) expressed primarily in the cell...
Topics
- Antineoplastic Agents
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Protein Kinase Inhibitors
- Sorafenib
- fms-Like Tyrosine Kinase 3